- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02346071
Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes
Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes: Randomized Trial
Background:
An increasing number of adolescents report recurrent functional somatic symptoms. Some experience persistent symptoms and may receive functional somatic syndromes (FSS) diagnoses (i.e. symptoms not attributable to any known conventionally defined physical disease), characterised by severe disability and reduced quality of life.
The aim of this study is to:
- Develop an Acceptance and Commitment Therapy (ACT)-based group intervention for adolescents with severe FSS (conceptualized as Bodily Distress Syndrome (BDS), see detailed description).
- Examine the efficacy of group based ACT in adolescents (aged 15-19 years) with severe FSS.
The ACT-based treatment, with 9 sessions of group therapy and one follow up meeting is compared to standard treatment/enhanced usual care, which is one single advisory consultation.
The study includes approximately 120 patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
An increasing number of adolescents report daily physical symptoms, with a current prevalence of 25%. A substantial proportion of these young people is examined in the health care system, most often with the conclusion that their symptoms cannot be explained in terms of a well-defined medical disease and are hence "stress-related" or "functional". Typically, the symptoms remit spontaneously after the patient is reassured. However, approximately 5-10% experience persistent symptoms and reduced functioning. They may receive diagnoses for functional somatic syndromes (FSS) such as chronic fatigue syndrome (CFS), fibromyalgia (FM), recurrent abdominal pain/irritable bowel syndrome (IBS) or idiopathic pain syndrome. These adolescents are at risk of social isolation, long term school-absence and reduced quality of life.
The aetiology of FSS is assumed complex, with interacting biological, psychological and environmental factors. Recent studies suggest that dysfunction of the stress-axes (e.g. the hypothalamic-pituitary-adrenal (HPA) axis and the autonomic nervous system) and activated inflammatory response are likely to play a role in the development and perpetuation of the symptoms in various FSS. Besides common pathophysiological mechanisms, FSS also show similarities in patient characteristics and treatment response, which speaks in favour of a common family of disorders. Recently, the unifying diagnostic category Bodily Distress Syndrome (BDS) was introduced. BDS is conceptualized as a (patho)physiologic response to prolonged or severe mental and/or physical stress in genetically susceptible individuals, and the diagnosis has been shown to encompass the majority of FSS.
FSS in adults can be managed effectively be means of psychological treatment, but the evidence for adolescents with severe FSS is sparse. Family based cognitive behavioural therapy (CBT) and internet-delivered CBT has proven effective for young patients with particular symptom profiles. However, the development of various specific treatments for each FSS or symptom profile is not an efficient strategy. Recent studies suggest that adult patients with various FSS sampled by the BDS diagnosis can feasibly be treated together, regardless of their main somatic complaint. The same may be true for adolescents, and hence the development of a common treatment for adolescents with various FSS or BDS may be advantageous, and facilitate further implementation in routine clinical care if the treatment is found effective.
Acceptance and Commitment Therapy (ACT), which derives from CBT, has shown promising results in children with chronic functional pain. Improvement could be demonstrated by less avoidance of important activities, better emotional wellbeing and less health care utilization. The aim of this project is to develop an ACT-based group intervention for adolescents with a range of FSS, i.e. conceptualised as severe BDS, and to evaluate its efficacy in a randomized controlled trial.
Method:
Patient population: 120 adolescents with BDS referred to The Research Clinic for Functional Disorders and Psychosomatics (FFL), Aarhus University Hospital. Patients are referred from general practitioners, specialists and hospital wards.
Diagnostic assessment: BDS will be diagnosed after a diagnostic work-up by a physician based on: 1) a review of former medical discharge letters, medical records and other relevant information, 2) SCAN (Schedules for Clinical Assessment in Neuropsychiatry) which screens for general psychopathology and contains a detailed section on BDS 3) screening for ADHD, autism and conduct disorder with screening questions from the child and adolescent psychiatric interview DAWBA (Development and Well Being Assessment), 4) a physical/neurological examination and 5) standard blood tests.
Procedure: Eligible patients, meeting all study criteria, are asked to participate in the RCT. The outcome measures will be filled in at baseline (T0), (i.e. at clinical assessment), before start of therapy (T1), (i.e. two months after baseline), after 8 sessions of therapy (T2), (i.e. 4 months after baseline), two weeks after 9 sessions of therapy (end of treatment, T3) (i.e. 5½ months after baseline) and at eight (T4) and twelve months (T5) after baseline. A physiological assessment of stress response and inflammatory response will be performed at T0 and T5.
Hypotheses:
Primary hypothesis: Patients randomized to ACT-based group therapy will report statistically and clinically significant better self-reported physical health twelve months after baseline, compared to patients receiving a standard psychiatric consultation only (SPC).
Secondary hypotheses: Compared to the control group (SPC), patients receiving ACT-group therapy will at eight and twelve months after baseline: 1. Report statistically and clinically significant reductions in somatic symptoms. 2. Report statistically and clinically significant lower symptom interference and at twelve months after baseline: 3. Show significant improvement in alterations of stress response and inflammatory response. The patients receiving ACT-group therapy will show good feasibility regarding treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8200
- Research Clinic for Functional Disorders and Psychosomatics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe Bodily Distress Syndrome (multi-organ type) of at least 12 months duration.
- 15-19 year-old.
- Born in Denmark or by Danish parents. Understand, speak and read Danish.
Exclusion Criteria:
- No informed consent.
- An acute psychiatric disorder demanding other treatment, or if the patient is suicidal.
- A lifetime diagnosis of psychosis, mania or depression with psychotic symptoms (ICD-10: F20-29, F30-31, F32.2, F33.3), serious cognitive deficits or developmental disorders such as mental retardation and autism (ICD-10: F70, F84).
- Abuse of narcotics, alcohol or medicine.
- Pregnancy at the time of inclusion.
- Not fit for group based treatment, e.g. patients with severe ADHD (ICD-10: F90), severe social phobia (ICD-10: F40.1) or conduct disorder (ICD-10: F91).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Enhanced Usual Care (EUC)
Clinical psychiatric and somatic assessment.
Standard psychiatric consultation (SPC) given 2 weeks after randomization.
|
All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization. The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services. |
Experimental: Acceptance and Commitment Therapy (ACT)
Clinical psychiatric and somatic assessment.
Standard psychiatric consultation (SPC) given 2 weeks after randomization.
ACT-based group therapy.
|
All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization. The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in SF36 (Assessment of physical health)
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Physical health measured with aggregate scores of the scales PF (physical functioning), BP (bodily pain) and VT (vitality).
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BDS checklist (Assessment of symptom severity)
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Questionnaire, patient rated.
Assessment of symptom severity.
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Change in SCL-somatization Questionnaire (Assessment of functional symptoms)
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Assessment of functional symptoms.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Change in Limitation index Questionnaire (Assessment of symptom interference)
Time Frame: At baseline (i.e. at clinical assessment) and 5½, 8 and 12 months after baseline (primary endpoint).
|
Questionnaire, patient and parent rated.
Assessment of symptom interference.
|
At baseline (i.e. at clinical assessment) and 5½, 8 and 12 months after baseline (primary endpoint).
|
PGIC (Patient Global Impression of Change)
Time Frame: At 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient and parent rated.
|
At 5½, 8 and 12 (primary endpoint) months after baseline.
|
Change in SF36 Questionnaire (Assessment of health related quality of life)
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire.
Patient rated.
Assessment of health related quality of life using Social Functioning Scale and Mental Health Scale.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Change in SCL-8, SCL-6, SCL-4 Questionnaire (Assessment of depression and anxiety)
Time Frame: At baseline (i.e. at clinical assessment) and 5½, 8 and 12 (primary endpoint) months after baseline .
|
Questionnaire, patient rated.
Assessment of depression and anxiety.
|
At baseline (i.e. at clinical assessment) and 5½, 8 and 12 (primary endpoint) months after baseline .
|
Change in HRV heart rate variability (assessment of stress response in various situations (resting state, standing, slow breathing and valsalva)
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Physiological assessment of stress response in various situations (resting state, standing, slow breathing and valsalva).
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Change in hair cortisol (Measurement of the level of stress-hormone cortisol in hair)
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Measurement of the level of stress-hormone cortisol in hair.
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Change in level of inflammatory and oxidative stress
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Biomarkers for inflammatory and oxidative stress (e.g.
IL1, IL6, TNF-alpha, high-sensitive CRP, neopterin, CD163, HO1, MCP1 but also newer proteo-based markers).
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Level of physical activity (Anthropometric measurements with accelerometer (Actigraph GT3X)
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Anthropometric measurements with accelerometer (Actigraph GT3X), duration 1 week (24h/day).
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Change in PSS (Perceived Stress Scale)
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Questionnaire, patient rated.
Assessment of self perceived stress level.
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in AFQ-Y8 (Avoidance and Fusion Questionnaire in Youth)
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Assessment of psychological flexibility.
Process measure.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Change in IPQ-R Illness Perceptions Questionnaire
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Process measure.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Change in BRIQ Behavioural Responses to Illness Questionnaire
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Assessment of illness related behaviour.
Process measure.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
FAD Family Assessment Devise
Time Frame: At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
Questionnaire, patient and parent rated.
Assessment of general family functioning.
Moderator.
|
At baseline (i.e. at clinical assessment) and 12 months after baseline (primary endpoint).
|
ESQ Experience of Service Questionnaire
Time Frame: 5½ months after baseline (end of treatment).
|
Questionnaire, patient rated.
Only given to patients in group based therapy.
Assessment of their treatment experience.
|
5½ months after baseline (end of treatment).
|
Change in Whiteley 8 (Assessment of health anxiety)
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Assessment of health anxiety.
Process measure.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Change in PIPS-12 Psychological Inflexibility in Pain Scale
Time Frame: At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
Questionnaire, patient rated.
Assessment of psychological inflexibility.
Process measure.
|
At baseline (i.e. at clinical assessment) and 2, 4, 5½, 8 and 12 (primary endpoint) months after baseline.
|
ECR-RS Experience in Close Relationships - relationship structure
Time Frame: At baseline (i.e. at clinical assessment)
|
Questionnaire, patient rated.
Assessment of attachment style.
Moderator.
|
At baseline (i.e. at clinical assessment)
|
Credibility/ expectancy questionnaire (Assessment of credibility regarding treatment)
Time Frame: App. two weeks after baseline (i.e. at standard psychiatric consultation (SPC))
|
Questionnaire, patient rated.
Assessment of credibility regarding treatment.
|
App. two weeks after baseline (i.e. at standard psychiatric consultation (SPC))
|
Life events Questionnaire (Registration of major negative life events)
Time Frame: At baseline (i.e. at clinical assessment)
|
Questionnaire, patient rated.
Registration of major negative life events.
|
At baseline (i.e. at clinical assessment)
|
Other treatment questionnaire (Registration of other received treatment (pharmacological, physiotherapy e.g.)
Time Frame: 12 months after baseline (primary endpoint).
|
Questionnaire, patient rated.
Registration of other received treatment (pharmacological, physiotherapy e.g.) during the follow-up period.
|
12 months after baseline (primary endpoint).
|
Registration of adverse events
Time Frame: 12 months after baseline (primary endpoint).
|
Questionnaire, patient rated.
Registration of potential adverse events during follow up period.
|
12 months after baseline (primary endpoint).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Charlotte U Rask, MD, PhD, Research Clinic for Functional Disorders and Psychosomatics, Aarhus University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CURKHK1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Somatoform Disorders
-
University Hospital, GrenobleTerminatedSomatoform DisordersFrance
-
University of Medicine and Dentistry of New JerseyNational Institute of Mental Health (NIMH); Rutgers, The State University of...CompletedSomatoform DisordersUnited States
-
University of BergenCompleted
-
University of AarhusKarolinska Institutet; Aarhus University HospitalCompleted
-
University of ManchesterCompleted
-
Brigham and Women's HospitalNational Institute of Mental Health (NIMH)CompletedSomatoform Disorders | HypochondriasisUnited States
-
Johannes Gutenberg University MainzUniversity of CologneUnknown
-
Goethe UniversityGerman Research FoundationCompletedSomatoform Disorders | HypochondriasisGermany
-
Brigham and Women's HospitalNational Institute of Mental Health (NIMH)Completed
-
Copenhagen Trial Unit, Center for Clinical Intervention...Bispebjerg HospitalCompletedHypochondriasis
Clinical Trials on Enhanced Usual Care (EUC)
-
Jeff BridgeCenters for Disease Control and PreventionRecruitingInsomnia | Suicidal Ideation | Suicide, AttemptedUnited States
-
Albert Einstein College of MedicineColumbia University; University of Rochester; Rutgers UniversityCompletedPediatric Obesity | Early Childhood CariesUnited States
-
University of North Carolina, Chapel HillUniversity of Houston; Colorado School of Public Health; University of North... and other collaboratorsEnrolling by invitationChild Behavior DisordersIndia
-
VA Office of Research and DevelopmentCompletedPTSD | Posttraumatic Stress DisorderUnited States
-
Ohio State UniversityNot yet recruitingPostpartum Depression | Postpartum Anxiety | Cardiometabolic SyndromeUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Not yet recruitingSuicidal Ideation | Suicide | Suicide PreventionPakistan
-
Massachusetts General HospitalNational Cancer Institute (NCI); Harvard Risk Management FoundationCompletedCancer | Breast Cancer | Head and Neck Cancer | Schizophrenia | Lung Cancer | Bipolar Disorder | Gastrointestinal Cancer | Severe Major DepressionUnited States
-
VA Office of Research and DevelopmentCompleted
-
University of North Carolina, Chapel HillUniversity of Colorado, Denver; American Academy of Child Adolescent Psychiatry... and other collaboratorsCompletedChild Behavior DisordersIndia
-
VA Office of Research and DevelopmentCompletedDiabetes MellitusUnited States